Immage Biotherapeutics Corp. (IMMG)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Immage Biotherapeutics Corp. (IMMG) with AI Score 48/100 (Weak). Immage Biotherapeutics Corp. is a financial services company that was formerly engaged in developing immunotherapy biologics. Market cap: 0, Sector: Financial services.
Last analyzed: Mar 18, 2026Immage Biotherapeutics Corp. (IMMG) Financial Services Profile
Immage Biotherapeutics Corp., operating within the financial services sector, previously focused on developing immunotherapy biologics. Currently a subsidiary of Coventry International Limited, the company has minimal business operations and a market capitalization of $0.00B, reflecting its transitional state and high-risk profile within the financial conglomerates landscape.
Investment Thesis
Investing in Immage Biotherapeutics Corp. presents a highly speculative opportunity given its current lack of significant business operations and its history of transitioning from a biotechnology focus. Key considerations include the potential for future strategic shifts under its parent company, Coventry International Limited. The company's high beta of 32.51 indicates extreme volatility. The absence of a dividend further underscores the speculative nature of this investment. Investors should closely monitor any announcements regarding future business plans or restructuring initiatives, as these will be critical value drivers. The company's P/E ratio is -0.07.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.00B, indicating a micro-cap valuation.
- P/E ratio of -0.07, reflecting current losses or minimal earnings.
- Beta of 32.51, indicating extremely high volatility compared to the market.
- No dividend yield, suggesting that the company does not currently distribute profits to shareholders.
- Currently has no significant business operations, marking a critical transition period.
Competitors & Peers
Strengths
- Subsidiary of Coventry International Limited, providing potential access to resources and capital.
- Previously engaged in biotechnology research, indicating some level of scientific expertise.
- Established corporate structure and history dating back to 2012.
Weaknesses
- Lack of significant business operations, resulting in minimal revenue generation.
- Small number of employees (3), limiting operational capacity.
- High beta of 32.51, indicating extreme volatility and risk.
- Uncertain strategic direction and dependence on decisions made by its parent company.
Catalysts
- Upcoming: Potential strategic repositioning within the financial services sector.
- Upcoming: Restructuring initiatives by Coventry International Limited to streamline operations.
- Ongoing: Technological innovation to enhance service offerings and improve efficiency.
- Ongoing: Regulatory compliance within the financial services sector.
- Upcoming: Formation of partnerships or alliances to expand market reach.
Risks
- Ongoing: Intense competition within the financial conglomerates sector.
- Ongoing: Regulatory changes and compliance requirements.
- Potential: Economic cycles and market volatility.
- Ongoing: Dependence on the strategic decisions and financial support of Coventry International Limited.
- Potential: Limited financial disclosure and transparency due to OTC Other listing.
Growth Opportunities
- Strategic Repositioning: Immage Biotherapeutics Corp. could explore new ventures or acquisitions within the financial services sector. The success of this pivot depends on identifying high-growth areas and integrating new businesses effectively. The timeline for this repositioning is uncertain, but strategic planning and execution could unfold over the next 2-3 years. Market size depends on the chosen sector, but potential areas include fintech or specialized financial services.
- Restructuring Initiatives: Coventry International Limited could initiate restructuring efforts to streamline Immage Biotherapeutics Corp.'s operations and reduce costs. This could involve divesting non-core assets or consolidating business units. The timeline for restructuring is likely within the next year, and the impact on the company's financial performance could be significant. The market size for cost optimization in financial services is substantial, with potential savings in operational expenses.
- Technological Innovation: Immage Biotherapeutics Corp. could invest in technological innovation to enhance its service offerings and improve efficiency. This could involve developing new software platforms or adopting advanced analytics tools. The timeline for technological innovation is ongoing, with continuous advancements in the financial services sector. The market size for fintech solutions is expanding rapidly, with opportunities for growth in areas such as digital payments and blockchain technology.
- Regulatory Compliance: Immage Biotherapeutics Corp. must navigate complex regulatory requirements within the financial services sector. Compliance with regulations such as Dodd-Frank and Basel III is essential for maintaining operational stability and avoiding penalties. The timeline for regulatory compliance is ongoing, with continuous updates and amendments to existing laws. The market size for regulatory compliance solutions is significant, with demand for specialized expertise and technology.
- Partnerships and Alliances: Immage Biotherapeutics Corp. could form strategic partnerships or alliances with other companies to expand its market reach and access new technologies. This could involve collaborating with fintech startups or established financial institutions. The timeline for partnerships and alliances is variable, depending on the specific opportunities that arise. The market size for collaborative ventures in financial services is substantial, with potential synergies in areas such as data analytics and customer acquisition.
Opportunities
- Potential for strategic repositioning within the financial services sector.
- Opportunity to leverage technology and innovation to enhance service offerings.
- Possibility of forming partnerships or alliances to expand market reach.
- Restructuring initiatives to streamline operations and reduce costs.
Threats
- Intense competition within the financial conglomerates sector.
- Regulatory changes and compliance requirements.
- Economic cycles and market volatility.
- Dependence on the strategic decisions and financial support of Coventry International Limited.
Competitive Advantages
- Currently, Immage Biotherapeutics Corp. does not possess a discernible moat due to its lack of significant business operations.
- Historically, its potential moat could have been based on proprietary immunotherapy technologies, but this is no longer applicable.
- Future competitive advantages will depend on strategic decisions made by Coventry International Limited and any new ventures the company pursues.
About IMMG
Immage Biotherapeutics Corp., founded in 2012 and headquartered in Bethesda, Maryland, initially operated under the name Epicure Charcoal, Inc. before rebranding in June 2015. The company's original focus was on developing novel immunotherapy biologics aimed at treating various cancers within the United States. However, as of the current date, Immage Biotherapeutics Corp. does not have significant business operations. The company functions as a subsidiary of Coventry International Limited. With a small team of three employees, the company's activities are limited. Its transition from a biotechnology focus to its current state reflects a significant shift in its operational direction. The company's market capitalization is $0.00B, and it trades on the OTC market.
What They Do
- Formerly engaged in developing novel immunotherapy biologics for cancer treatment.
- Currently operates as a subsidiary of Coventry International Limited.
- Maintains a corporate presence in Bethesda, Maryland.
- Has a small team of three employees.
- Focuses on financial services, although its specific activities are limited.
- Underwent a name change from Epicure Charcoal, Inc. in 2015.
Business Model
- Currently, the business model is not operational due to the lack of significant business activities.
- Previously focused on developing and commercializing immunotherapy biologics.
- Functions as a subsidiary, potentially receiving funding or strategic direction from Coventry International Limited.
Industry Context
Immage Biotherapeutics Corp. operates within the financial conglomerates sector, a segment characterized by diverse business activities and complex organizational structures. The broader financial services industry is subject to regulatory changes, economic cycles, and technological advancements. Given Immage Biotherapeutics Corp.'s current state of minimal operations, its positioning within this landscape is highly dependent on strategic decisions made by its parent company, Coventry International Limited. Competition within the financial conglomerates sector is intense, with established players like AXTG and BITCF.
Key Customers
- Historically, potential customers included patients and healthcare providers in the oncology space.
- Currently, the primary customer is Coventry International Limited, its parent company.
- Future customers will depend on the company's strategic direction and any new ventures it undertakes.
Financials
Chart & Info
Immage Biotherapeutics Corp. (IMMG) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Friday
· Oct 4, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IMMG.
Price Targets
Wall Street price target analysis for IMMG.
MoonshotScore
What does this score mean?
The MoonshotScore rates IMMG's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Zhi Cong Mou
Unknown
Zhi Cong Mou currently manages three employees at Immage Biotherapeutics Corp. Information regarding Zhi Cong Mou's detailed career history, education, and previous roles is not available. His leadership is pivotal in navigating the company's transition and potential future ventures, given its current state of minimal operations.
Track Record: Due to the limited business operations of Immage Biotherapeutics Corp., Zhi Cong Mou's track record is difficult to assess. His strategic decisions will be critical in determining the company's future direction and success. There is no available information regarding key achievements or company milestones under his leadership.
IMMG OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Immage Biotherapeutics Corp. may not meet the minimum financial standards required for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited financial disclosure and may be subject to greater risks compared to those listed on national exchanges like NYSE or NASDAQ. This tier is generally reserved for companies with distressed financials, penny stocks, or those that choose not to comply with higher reporting standards.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Financial Disclosure: The unknown disclosure status increases the risk due to a lack of transparency.
- Low Liquidity: The OTC Other listing and minimal operations suggest very low trading volume and wide bid-ask spreads.
- Speculative Nature: The absence of significant business operations makes the investment highly speculative.
- Regulatory Scrutiny: OTC-listed companies are subject to less regulatory oversight compared to exchange-listed companies.
- Potential for Delisting: Failure to meet minimum listing requirements could result in delisting from the OTC market.
- Verify the company's financial disclosure status and obtain access to any available financial reports.
- Assess the company's management team and their experience in the financial services sector.
- Evaluate the company's strategic plans and potential for future growth.
- Review the company's legal and regulatory compliance status.
- Analyze the company's capital structure and any outstanding debt obligations.
- Monitor trading volume and bid-ask spreads to assess liquidity.
- Understand the ownership structure and any potential conflicts of interest.
- Subsidiary of Coventry International Limited: This affiliation provides some level of oversight and potential financial support.
- Established Corporate History: The company has been in existence since 2012, indicating some level of organizational stability.
- Corporate Headquarters: The company maintains a physical presence in Bethesda, Maryland.
- Name Change: The company changed its name in 2015 to Immage Biotherapeutics Corp.
IMMG Financial Services Stock FAQ
What does Immage Biotherapeutics Corp. do?
Immage Biotherapeutics Corp. currently functions as a subsidiary of Coventry International Limited and does not have significant business operations. Previously, the company was engaged in developing novel immunotherapy biologics to treat various cancers in the United States. The company's transition from a biotechnology focus to its current state reflects a significant shift in its operational direction. The company's future activities will depend on strategic decisions made by its parent company.
What do analysts say about IMMG stock?
Given the company's lack of significant business operations and OTC Other listing, there is limited analyst coverage of IMMG stock. Key valuation metrics such as revenue and earnings are not applicable due to the company's current state. Any future analyst coverage will likely depend on strategic decisions made by Coventry International Limited and any new ventures the company undertakes. Investors should conduct their own due diligence and assess the risks associated with investing in a micro-cap OTC stock.
What are the main risks for IMMG?
The main risks for IMMG include its lack of significant business operations, limited financial disclosure due to its OTC Other listing, and dependence on the strategic decisions of its parent company, Coventry International Limited. The company's high beta of 32.51 indicates extreme volatility. Additionally, the low liquidity of the stock can make it difficult to buy or sell shares without significantly impacting the price. Investors should carefully consider these risks before investing in IMMG.
What are the key factors to evaluate for IMMG?
Immage Biotherapeutics Corp. (IMMG) currently holds an AI score of 48/100, indicating low score. Key strength: Subsidiary of Coventry International Limited, providing potential access to resources and capital.. Primary risk to monitor: Ongoing: Intense competition within the financial conglomerates sector.. This is not financial advice.
How frequently does IMMG data refresh on this page?
IMMG prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven IMMG's recent stock price performance?
Recent price movement in Immage Biotherapeutics Corp. (IMMG) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Subsidiary of Coventry International Limited, providing potential access to resources and capital.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider IMMG overvalued or undervalued right now?
Determining whether Immage Biotherapeutics Corp. (IMMG) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying IMMG?
Before investing in Immage Biotherapeutics Corp. (IMMG), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The company's financial performance and future prospects are highly uncertain due to its lack of significant business operations.
- Investment in micro-cap OTC stocks carries significant risks.